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Abstract: As the COVID-19 pandemic continues, children can be infected with the virus that causes COVID-19. Clinical symptoms of
children with COVID from China, where the disease was first reported, generally were less severe than adults. However, at the end of
April 2020 in Europe, it was observed that some children with SARS-CoV-2 infection developed fever, abdominal pain, shock, myocardial
insufficiency and they needed to be taken care of in intensive care unit. This new disease has been called multisystem inflammatory
syndrome in children (MIS-C). Although the pathogenesis of MIS-C is unclear, it progresses with signs of multiorgan involvement as
a result of uncontrolled inflammation of the immune system and even causes death. Therefore, the diagnosis and treatment of patients
with MIS-C should be managed quickly. In this review, the pathophysiology, clinical and laboratory findings, diagnostic methods, and
treatment regimens of MIS-C were discussed.
Key words: Multisystem inflammatory syndrome, COVID-19, children

1. Introduction
As the COVID-19 pandemic continues, it is becoming
increasingly clear that severe clinical manifestations of
SARS-CoV-2 infection remain rare in children, accounting
for only 1.5% of all COVID-19 hospital admissions [1].
Clinical symptoms of children with COVID from China,
where the disease was first reported, generally were less
severe than adults [2]. However, on April 27, 2020, The
Pediatric Intensive Care Society of the United Kingdom
released an alert regarding an increased number of children
presenting with fever, shock, abdominal pain, vomiting,
and diarrhoea , with disease features that overlap with
Kawasaki Disease (KD) and Toxic Shock Syndrome (TSS),
many of whom had tested positive for COVID-19 [3]. This
syndrome has been described in Europe as transient SARSCov-2 associated pediatric inflammatory multisystem
syndrome (PIMS-TS), while Center for Disease Control
and Prevention (CDC) reported that multiple systemic
inflammatory syndrome is associated with COVID-19
(MIS-C), between March 1 and May 10, 2020 [4,5].
Children with MIS-C may have a fever and various
symptoms, including abdominal pain, vomiting,
diarrhea, neck pain, rash, bloodshot eyes, or feeling
extra tired. Some features of MIS-C resemble KD, TSS,
and secondary hemophagocytic lymphohistiocytosis/

macrophage activation syndrome. Kawasaki disease is
a syndrome of unknown cause that results in a fever and
mainly affects children under 5 years of age. It is a form
of vasculitis, where blood vessels become inflamed.
Although classic Kawasaki’s disease disproportionately
affects Asian children and young children, MIS-C that
is associated with Covid-19 appears to occur among
children of all ethnic backgrounds and is detected in
older children [6]. The relationship of MIS-C to SARSCoV-2 infection suggests that the pathogenesis involves
post-infectious immune dysregulation. However, the
possibility that MIS-C is more consistent with a subacute
infection than a post-infectious syndrome was not fully
considered.
2.Epidemiology
In April 2020, cases resembling incomplete Kawasaki
disease or toxic shock syndrome thought to be associated
with COVID-19 were reported first time from UK [3].
Then, an increase was observed in the reporting of similar
cases from various countries around the world, especially
in New York (USA). Based on epidemiological data from
the UK, New York, and Italy, it was also noted that there
was a delay of several weeks between when COVID-19
cases were most common in the community and when the
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number of MIS-C cases was the highest. Epidemiological
data clearly indicate that SARS-CoV-2 is the trigger
for MIS-C, which typically occurs about 1 month after
infection.
As of October 1, 2020, the number of patients meeting
the case definition for MIS-C in the United States
surpassed 1000. In 2021, this number surpassed 2000 as
of 2021 February 1 and 3000 as of April 1 [7]. In USA,
a descriptive study showed that the peak in the number
of MIS-C cases followed the peak in the number of cases
of laboratory-confirmed SARS-CoV-2 infection by 31
days. From March 1 through May 10, 2020, the incidence
of laboratory-confirmed SARS-CoV-2 infection was 322
per 100,000 persons younger than 21 years of age, and the
incidence of MIS-C was 2 per 100,000 persons younger
than 21 years of age [8].
There has been a striking paucity of MIS-C cases from
East Asia. Only two cases of MIS-C have been reported
to date in South Korea During May–November 2020; a
total of 2287 COVID-19 cases in persons 0–19 years of age
was reported, and no cases have been reported in Japan
or China as opposed to the higher number of cases from
the Americas, Europe, Africa, South Asia, and the Middle
East [9,10].
3.Pathophysiology
The reasons for the milder course of SARS-CoV-2 infection
in children compared to adults have been investigated,
but the reasons have not been clearly determined. Several
theories have been discussed involving differences in the
immune system, such as thymic function difference, crossreactive immunity against other coronaviruses, as well as
differences in the expression of the angiotensin converting
enzyme 2 (ACE2) receptor that the virus uses to enter
the cell [11]. The immune system undergoes substantial
changes from birth to adulthood [12]. In a study, it has
been reported that patients with MIS-C have ineffective
and reduced neutralizing antibody activity against SARSCov-2 compared to adults who have severe COVID-19
and recovered [13].
Generally, viruses are not detected in the respiratory
tract of patients with MIS-C, but other parts of the body,
such as the gastrointestinal tract, have not been studied
sufficiently [14]. A recent study revealed the presence
of SARS-CoV-2 in lungs, heart, kidneys by at least one
method (RT-PCR, IHC, or EM), and in endothelial cells
of heart and brain in two patients with MIS-C (IHC).
And 2 in the brain tissue of a child with MIS-C with acute
encephalopathy, and in the intestinal tissue of a child
with acute colitis [15]. The presence of SARS-CoV-2 in
several organs, associated with cellular ultra-structural
changes, reinforces the hypothesis that a direct effect of
SARS-CoV-2 on tissues is involved in the pathogenesis
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of MIS-C. According to Schwarz’s hypothesis, there may
be persistent infection [16]. This hypothesis said that in
MIS-C, immune responses that have not fully controlled
an ongoing infection might allow persistent activation
of the intrinsic immune system. This persistent innate
immune inflammatory response probably occurs because
of the ability of SARS-CoV-2 to block type 1 and type 3
interferon response signalling to the adaptive immune
system without disrupting cytokine production. If MIS-C
is confirmed to be caused by ongoing infection, this finding
might also have important implications for antiviral
treatment of adults with prolonged symptoms after SARSCoV-2 infection.
In another study, the inflammatory differences
observed in children with KD and MIS-C such as
interleukin-17A mediated hyperinflammation response.
Additionally, differences were found in T cells subsets and
cytokine mediators. It was found that diffuse endothelial
involvement was higher in MIS-C than KD. In this study,
autoantibody formation hypothesis was proposed as the
cause of this immune response, and it was thought that
these autoantibodies contributed to damage in MIS-C
[17]. Some studies investigate the therapeutic potential of
peptide mimetics of SARS-CoV-2 spike SAg-like region
in COVID-19-induced hyperinflammatory syndrome
similar to toxic shock syndrome (TSS) [18].
Angiotensin-converting enzyme 2 receptor is
expressed in the heart, kidneys and testicles, and lungs.
It is commonly found in human alveolar epithelial cells,
small intestine epithelial cells, arterial smooth muscle,
and vascular endothelial cells [19]. Increasing evidence
suggests that ACE2 enzyme activity has a protective role in
cardiovascular disease; ACE2 loss can be harmful because
it can lead to worsening of heart function and progression
of cardiovascular disease [20]. Therefore, ACE2 receptor
loss due to SARS-CoV-2 infection may lead to myocardial
damage [21,22].
4.Clinical presentation
Clinical presentation of MIS-C is dominated by significant
inflammation. Most affected children are previously
healthy and have no history of comorbid diseases (Table
1). However, it is noteworthy that the rate of obese patients
has increased in some studies [23,24].
Abbreviations:
ARDS
=
acute
respiratory
distress syndrome; BNP = brain natriuretic peptide;
PICU =pediatric intensive care unit; IQR = interquartile
range; NT-proBNP = N-terminal pro b-type
natriuretic peptide; PCR = polymerase chain reaction.
Fever is the most important finding found in MIS-C.
Presence of resistant and prolonged fever is different
from many diseases [25]. In addition to the presence of
fever, gastrointestinal symptoms, including vomiting,
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Table 1 . Demographic and clinical characteristics of MIS-C patients announced by CDC (38).
Clinical characteristics

Total cases (%)

Total cases

570 (100)

Sex
Female
Male

316 (55.4)
254 (44.6)

Age (year), median (IQR)

8 (4–12)

Death

10 (1.8)

Hospitalization (day) IQR
1
2-7
8-14
≥ 15
Unknown

6 (4-9)
16 (3.2)
304 (60.2)
149 (29.5)
36 (7.1)
65 (-)

PICU

364 (63.9)

Hospitalization of PICU(day) (IQR)

5 (3–7)

Obezite
Chronic lung disease

146 (25.6%)
48 (8.4%)

No. of organ systems involved
2-3
4-5
≥6

80 (14.0%)
351 (61.6%)
139 (24.4%)

Clinical characteristics

Total cases (%)

Cardiovasculer
Shock
Troponin elevation
Elevated BNP/NT-Pro BNP
Congestive heart failure
Cardiac dysfunction
Miyocarditis
Coronary artery dilatation
Hypotension
Pericardial effusion
Mitral regurgitation
Dermatologic/ mucocutaneous
Rash
Mucocutaneous lesions
Conjunctival injection
Hematologic
Elevated D–dimer
Thrombocytopenia
Lymphopenia
Respiratory
Cough
Shortness of breath
Chest pain or /tightness
Pneumonia†
ARDS
Pleural effusion§
Neurologic
Headache
Renal
Acute kidney injury
Other
Periorbital edema
Cervical lymphadenopathy >1.5 cm diameter

493 (86.5)
202 (35.4)
176 (30.9)
246 (43.2)
40 (7)
207 (40.6)
130(22.8)
95 (18.6)
282 (49.5)
122 (23.9)
130 (25.5)
404 (70.9)
315 (55.3)
201 (35.3)
276 (48.4)
421 (73.9)
344 (60.4)
176 (30.9)
202 (35.4)
359 (63)
163 (28.6)
149 (26.1)
66 (11.6)
110 (19.3)
34 (6)
86 (15.8)
218 (38.2)
186 (32.6)
105 (18.4)
105 (18.4)
27 (4.7)
76 (13.3)

Gastrointestinal symptom
Abdominal pain
Vomiting
Diarrhea

518 (90.9)
353 (61.9)
352 (61.8)
303 (53.2)

Abbreviations: ARDS = acute respiratory distress syndrome; BNP = brain natriuretic peptide; PICU =pediatric intensive care unit;
IQR = interquartile range; NT-proBNP = N-terminal pro b-type natriuretic peptide; PCR = polymerase chain reaction.

abdominal pain and / or diarrhea, mucocutaneous
symptoms, including conjunctivitis and rash reminiscent
of KD, and symptoms such as headache, irritability, and
encephalopathy may also include neurological symptoms
[26,27]. These findings are nonspecific and may occur
with noninfectious etiologies such as oncological or
inflammatory conditions, as well as other infectious
diseases. More rarely, cases who underwent laparotomy
for reasons such as mesenteric lymphadenitis and

peritonitis have been reported [28]. In some patients,
respiratory distress due to hypotension requires inotropic
support, and, in others, due to cardiac dysfunction, it
requires noninvasive or invasive mechanical ventilation,
and even requires admission to the pediatric intensive
care unit. In a patient with suspected multiple systemic
inflammatory disease, if there is a persistent fever and a
history of exposure to the SARS-CoV2 virus, the presence
of at least two of the listed findings is recommended to

3275

HANÇERLİ TÖRÜN et al. / Turk J Med Sci
perform further investigations to show the diagnosis
of MIS-C. These findings are as follows: rash (may be
maculopapular and / or polymorphic and / or petechial
rash; vesicular rash is not expected) gastrointestinal
complaints (diarrhea, abdominal pain, vomiting) handstanding edema, oral mucosa changes (red and / or
cracked lips, strawberry tongue or oropharyngeal mucosa
erythema), conjunctivitis (non-bilateral exudative),
lymphadenopathy and neurological symptom (altered
mental perception, encephalopathy, focal neurological
findings, meningismus or papilledema) [27]. In the
study of Whittaker et al. consisting of 58 cases, all of the
patients presented with fever lasting 3–19 days, variable
combinations of sore throat (n=6, 10%), headache (n=15,
26%), abdominal pain (n=31, 53%) and erythematous rash
(n=30, 52%). More rarely, cases with conjunctivalerythema
(n=26, 45%), lymphadenopathy, mucous membrane
changes, red chapped lips, swelling in the hands and
feet have also been reported. In another study, fever (>
38.5 °C) and malaise were found in all patients, while
gastrointestinal symptoms were found in 80% of the
patients. Among the symptoms suggestive of KD, skin
rash, ileitis, cervical lymphadenopathy, and meningismus
were observed to be frequent, and all of them met the
criteria for complete KD [24]. In a study conducted in
the United States of America, fever was found in all 186
MIS-C cases, most of the cases had gastrointestinal system
(92%) complaints, and cardiovascular involvement (80%)
was found to be common in the cases [25]. It was observed
that 10 patients were admitted to the hospital with a fever
lasting an average of six days, and half of the patients had
classical KD findings, while the other half had incomplete
KD findings. In addition, clinical signs of hypoperfusion
and hypotension meeting KDSS criteria were detected in
5 cases. Cardiac manifestations are common, including
ventricular dysfunction, coronary artery dilation and
aneurysms, arrhythmia, and conduction abnormalities
[29].
Studies show that the rate of intensive care
hospitalization varies between 30%–80% [27,28,30].
Similarly, the need for inotropes was found to be 30%–
50% in shock rates. Mortality rates vary; while death was
reported in four (2%) cases in Feldstein et al.’s study, death
was reported in five cases (11%) in the study of Mamishi et
al. [25,31]. In addition, there are studies in which no deaths
were reported [27,30]. The clinical features of severe acute
COVID-19, and MIS-C may overlap. But different clinical
findings and organ system involvement may be helpful at
this point [32,33,34].
Most pediatric cases of severe acute COVID-19 occur
in children with underlying health problems; however,
most of the children with MIS-C were previously healthy.
Respiratory symptoms are rare in patients with MIS-C but
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are more common in patients with severe acute COVID-19.
Also, gastrointestinal symptoms, mucocutaneous findings,
myocardial dysfunction, and shock are more common in
MIS-C than in severe acute COVID-19.
5.Laboratory findings
Laboratory findings are variable. In a metaanalysis of
66 studies in children that included 9335 children with
documented SARS-CoV-2 , the laboratory abnormalities
were (mean proportion) as follows[35]:
●Elevated C-reactive protein (CRP) – 54%
●Elevated serum ferritin – 47%
●Elevated lactate dehydrogenase – 37%
●Elevated D-dimers – 35%
●Elevated procalcitonin – 21%
●Elevated erythrocyte sedimentation rate – 19%
●Elevated leukocytes – 20%
●Lymphocytopenia – 19%
●Lymphocytosis – 8%
●Elevated serum aminotransferases – 30%
●Elevated creatine kinase myocardial band – 25%
An exaggerated response may indicate MIS-C. Serum
C reactive protein (CRP), erythrocyte sedimentation rate
(ESR), fibrinogen, D-dimer, ferritin, lactatedehydegenase
(LDH), interleukin 6 (IL-6) are increased; lymphopenia,
thrombocytopenia, hypoalbuminemia and hyponatremia
can be detected. In Whittaker et al.’s study, the mean CRP
value (229 mg/L) was found to be very high [27]. In another
study, the mean ESR was 72 mm/h, and the mean ferritin
value was 1176 ng/mL. Eight of the cases (84.5%) had
lymphopenia and hyponatremia, while seven (87%) had
mild transaminase elevation (aspartate aminotransferase
87 U / L [SD 70]; alanine aminotransferase 119 U / L [ SD
217]), and triglyceride elevation. (239 mg / dL [SD 108])
was detected. In addition, increased fibrinogen (621 mg /
dL [182]) was observed in nine cases (90%) and increased
D-dimer (3798 ng / mL [SD 1318]) in eight cases [30].
Electrocardiogram (ECG), cardiac enzymes (troponin,
B-type natriuretic peptide [BNP] / N-terminal-pro-B-type
natriuretic peptide [NT-proBNP]) and echocardiography
are recommended for cardiac evaluation. In a study
evaluating cardiac enzyme elevation, it was observed that
trop824onin elevation was observed in 68% (34/50) of the
cases, while NT-proBNP increased in 83% [30].
MIS-C associated with COVID-19 is characterized
predominantly by cardiovascular abnormalities, although
solid visceral organ, gall bladder, and bowel abnormalities,
as well as ascites, are also seen, reflecting a multisystemic
inflammatory process. Blumfield et al.’s study revealed that
cardiomegaly (63%), congestive heart failure or cardiogenic
pulmonary edema (56%), atelectasis (56%), pleural
effusions (44%), acute respiratory distress syndrome
(13%), and pneumonia (6%) were shown on chest
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radiography and abdominal imaging findings (ultrasound,
CT, and radiography), together with small-volumea scites
(38%), hepatomegaly (38%), echogenic kidneys (31%),
bowel wall thickening (19%), gall bladder wall thickening
(19%), mesenteric lymphadenopathy (13%), splenomegaly
(16%), and bladder wall thickening (6%) [28].
6.Diagnosis
The MIS-C diagnostic criteria announced by the World
Health Organization and CDC are summarized in Table
2 [4,36]. The definitions require patients to be less than 21
years old (CDC criteria) or less than 19 years old (WHO
criteria) and to have evidence of recent or current SARSCoV-2 infection or exposure (CDC only), the presence
of documented fever, elevated markers of inflammation,
at least two signs of multisystem involvement. Evaluation
of a diagnosis for MIS-C must include research for other
possible causes. This disease is temporarily associated
with SARS-CoV-2 infections and has been reported as
clusters of cases 2–6 weeks after the highest incidence
of COVID-19 cases, typically in geographic areas with
COVID-19 disease burden. In MIS-C, the timing of onset
of symptoms is variable. The usual duration between acute
SARS-CoV2 infection and onset of MIS-C symptoms is
2 to 6 weeks. However, in literature, rare cases of MIS-C
occurring >6 weeks after the acute infection have been
reported [37]

All patients with suspected MIS-C should demonstrate
exposure to the SARS-CoV-2 virus. RT-PCR test should
be performed to detect the SARS-CoV-2 virus at the time
of application. If initially RT-PCR is detected negative, at
least 24 h after the second test. In studies, it was observed
that most of the cases (80%–90%) were positive for SARSCoV-2 antibodies, RT-PCR positivity, and antigenicity was
found to be positive in very few (20%–40%) cases [38,39].
Acute phase response patients with suspected MIS-C
should demonstrate exposure to the SARS-CoV-2 virus.
RT-PCR test should be performed to detect the SARSCoV-2 virus at the time of application. Initially RTPCR is detected negative, at least 24 h after a second
test application. In studies, it was observed that most of
the cases (80%–90%) were positive for SARS-CoV-2
antibodies, RT-PCR positivity and antigenicity were found
to be positive in very few (20%–40%) of the cases [32].
7.Differrential diagnosis
MIS-C may show similar features with childhood diseases
such as sepsis, KH, KDSS, macrophage activation
syndrome (MAS), and TSS [33]. Sepsis is an important
condition in children presenting with fever, shock, and
high inflammatory markers. Blood cultures should be sent
from all children with moderate to severe suspicion of
MIS-C, and empirical antibiotics should be administered
while the culture results are awaited. Some clinical

Table 2. Diagnostic Criteria for MIS-C
Centers for Disease Control and Prevention (CDC) (4)

World Health Organization (WHO) (36)

· An individual aged <21 years having fever*, laboratory
evidence of inflammation**, and evidence of clinically severe
illness requiring hospitalization, with multisystem (>2)
organ involvement (cardiac, renal, respiratory, hematologic,
gastrointestinal, dermatologic, or neurological);
AND
· No alternative plausible diagnoses;
AND
· Positive for current or recent SARS-CoV-2 infection by RTPCR, serology, or antigen test; or exposure to a suspected or
confirmed COVID-19 case within the 4 weeks prior to the onset
of symptoms.
*Fever >38.0°C for ≥24 h, or report of subjective fever lasting
≥24 h
**Including, but not limited to, one or more of the following: an
elevated C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic
acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated
neutrophils, reduced lymphocytes and low albumin.

- Children and adolescents 0–19 years of age with fever > 3 days
AND two of the following:
1. Rash or bilateral non-purulent conjunctivitis or muco-cutaneous
inflammation signs (oral, hands or feet).
2. Hypotension or shock.
3. Features of myocardial dysfunction, pericarditis, valvulitis, or
coronary abnormalities (including ECHO findings or elevated
Troponin/NT-proBNP).
4. Evidence of coagulopathy (by PT, PTT, elevated d-Dimers).
5. Acute gastrointestinal problems (diarrhoea, vomiting, or
abdominal pain).
AND
Elevated markers of inflammation such as ESR, C-reactive protein,
or procalcitonin.
AND
No other obvious microbial cause of inflammation, including
bacterial sepsis, staphylococcal or streptococcal shock syndromes.
AND
Evidence of COVID-19 (RT-PCR, antigen test or serology positive),
or likely contact with patients with COVID-19.
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features may help distinguish MIS-C from bacterial
sepsis. For example, cardiac involvement, especially
coronary artery involvement, is rare in bacterial sepsis.
Also, microbiological tests (SARS-CoV-2 antigen /
antibody / RT-PCR tests, bacterial cultures) are required
to differentiate the disease.
Kawasaki disease is a vasculitis that usually occurs in
young children and involves medium-sized vessels such
as coronary arteries. It is the most common cause of
childhood acquired heart disease in developed countries;
features include rash, cervical lymph node enlargement,
ocular and oral mucosal changes, hand-foot changes, as
well as fever lasting at least five days. Apart from this, liver,
lungs, gastrointestinal system, central nervous system
and joints may be involved. Some clinical and laboratory
findings may be useful in differentiating MIS-C and KD.
Increased acute phase responses are seen in Kawasaki
disease similar to MIS-C, while thrombocytosis is more
common. Prominent abdominal pain and lymphopenia
are more likely revealed in MIS-C disease [30]. In addition,
patients with MIS-C are much more likely to exhibit
cardiac dysfunction and especially hypotension compared
to patients with KD. One of the cardiac markers, NTProBNPKH, is a potential marker and can be detected at
levels as high as 7000 pg / mL in MIS-C. Values exceeding
10000 pg / mL are frequently reported (31). It is thought
that Kawasaki disease is triggered by a viral infection,
which is likely to occur in winter and spring months and
causes an inflammatory response in genetically susceptible
children (32). Kawasaki disease shock syndrome less than
5% of children with KD present with bacterial diseaselike shock and hypotension and have higher neutrophil

and band counts, lower platelet counts, lower hemoglobin
levels, and higher CRP levels compared to KD (Table 3).
Toxic shock syndrome is caused by uncontrolled
activation of the immune system due to superantigens that
stimulate T cells nonselectively. It is caused by bacterial
species such as Staphylococcus aureus and Streptococcus
pyogenes. The clinical picture of toxic shock syndrome
was hypotension, diffuse erythrodermic rash, diffuse
mucosal involvement, and multiple systemic dysfunction
(renal, hepatic, hematological, respiratory, muscular, and
neurological). Toxic shock syndrome may be similar to
KDSS, but patients with TSS tend to be older (9 ± 4.6 years
and 3 ± 3.4 years, respectively). In addition, TSS is more
likely to have normal hemoglobin levels and low platelet
counts [31].
Hemophagocytic lymphohistiocytosis (HLH) is a
disease that develops secondary to anomalies in genes
regulating the degranulation of natural killer cells and
cytotoxic CD8 + lymphocytes, leading to a “cytokine
storm” by eliminating antigenic stimuli that lead to
cellular activation. High levels of proinflammatory
cytokines, then, activate other cells of the immune system
(macrophages), leading to organ damage and characteristic
hemophagocytosis of affected organs. Secondary HLH
(MAS) is triggered by an autoimmune or autoinflammatory
condition; drugs, malignancy or infections, and especially
viral infections are well-known triggers. In macrophage
activation syndrome, there is typically high levels of
evidence of systemic inflammation. Organ dysfunction
such as coagulopathy, liver failure, central nervous system
dysfunction, and cardiac dysfunction can be seen with
CRP, triglycerides, and D-dimer. Especially in patients

Table 3. Clinical characteristics of Kawasaki Disease and MIS-C
Kawasaki Disease

MIS-C

Age

1–4 yearsold

Mean 8 years old (2-17 y)

Presenting symptoms

Fever for 5 days plus 4/5:
conjunctivitis,rash,adenopathy, strawberry
tounge,hand/food swelling

Persistent fever >24 h, GI symptoms, rash,
conjunctivitis

Rash

Yes; polymorphus

Yes, less common to have mucosal involment

Gastrointestinal symptoms

Less common

Very common (abdominaş pain, vomiting,
diarrhea

Labs

Leukocytosis, Trombocytosis, elevated CRP,ESR,

Lympocytopenia, Trombocytopenia,
Elevated CRP, ESR, elevated cardiac markers

Echocardiyogram

Coronory artery abnormalities

Decreased left ventriculer function, coronoary
artery abnommalities

Treatment

IVIG, aspirin

Generally supportive; anticoagulant, steroids,
IL-1/IL-6 antagonists
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with MAS, leukocyte count, thrombocyte count, and ESR
tend to be suppressed [38].
Other viral pathogens that should be considered in
differential diagnosis with multiple systemic inflammatory
syndrome include Epstein-Barr virus, cytomegalovirus,
adenovirus, and enteroviruses; in these infections, they
may present with multiple systemic involvement and / or
myocarditis. These viruses rarely cause severe multisystemic
involvement, especially in immunocompromised children.
Serological tests and RT-PCR can be used for this purpose.
8.Treatment
The aim of treatment in MIS-C is to reduce systemic
inflammation and restore organ function. By definition,
MIS-C is a multisystem disease, and caring for affected
children requires the coordination of many different
specialties. These are as follows:
-Pediatric infectious diease specialist,
-Pediatric rheumatology specialist,
-Pediatric cardiolojist,
-Pediatric intensive care specialist,
-Pediatric hematology specilaist.
Treatment depends on the clinical condition of the
patient. Some interventions, such as empirical antibiotics,
intravenous immune globulin (IVIG), and prophylactic
antithrombotic therapy are suitable for most patients with
moderate to severe symptoms [38]. The American Society

of Rheumatology recommends routine IVIG treatment
in cases with a diagnosis of moderate and severe MIS-C
and also recommends IVIG for all patients with signs of
Kawasaki disease. IVIG is also recommended in situations
involving any of the following:
-Shock,
-Cardiac involvement, including any of the following;
-Supression of left ventricular function on
echocardiolography,
-Coronary artery abnormalities (dilatation or
aneurysm),
-Arrhytmia,
-High BNP/NT-Pro BNP and/or troponin levels.
-Other serious symptoms requiring pediatric intensive
care unit.
Patients who are being investigated for multiple
systemic inflammatory syndrome should first undergo
diagnostic evaluation if there is no life-threatening
condition (Figure 1). These cases should be investigated
before immunomodulatory therapy in terms of MIS-C
as well as other possible infection and noninfectious
related conditions. However, if there are life-threatening
symptoms in the patients, it may be necessary to start
immunomodulatory treatment without waiting for the
completion of the full diagnosis evaluation [32].
Step-by-stepprogression
of
immunomodulatory
therapies should be used to treat MIS-C (Figure 2).

Figure 1. Clinical aproach to possiple MIS-C. Adapted from reference 32: Henderson LA, Canna SW, Friedman KG, Gorelik
M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory
Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis
& rheumatology (Hoboken, NJ). 2021;73(4):e13-e29
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Figure 2. Clinical follow-up of MIS-C. Adapted from reference 32: Henderson LA, Canna SW,
Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology
Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSCoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis & rheumatology
(Hoboken, NJ). 2021;73(4):e13-e29

Intravenous immunoglobulin (IVIG) is considered firstline immunomodulatory therapy. Patients with features
similar to Kawasaki disease without shock and cardiac
involvement can initially be followed up conservatively.
However, IVIG is typically recommended if the patient’s
clinical condition worsens or in the presence of persistent
fever or elevated inflammatory markers, including elevated
ferritin levels [38].
Glucocorticoids should be used as adjunctive therapy
in patients with severe disease or as intensification
therapy in patients with refractory disease. Intravenous
immunoglobulin should be given to patients who are
hospitalized and / or fully meet the KD criteria. Highdose IVIG (typically 2 g / kg based on ideal body weight)
should be used for the treatment of MIS-C (Figure 2).
For patients without Kawasaki disease-like features,
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a lower dose is typically recommended (1 g / kg in 8 to
12 h). kg). The cardiac functions of patients, who are
planned to use intravenous immunoglobulin, should be
evaluated, and IVIG should be followed closely in patients
with depressed cardiac functions, and diuretics should be
administered if necessary. In addition, in some patients
with cardiac dysfunction, IVIG may be given in divided
doses (1 g / kg per day for 2 days). Low and medium doses
of glucocorticoids (1–2mg / kg / day) should be given
in two divided doses together with IVIG as adjunctive
therapy in the treatment of patients with shock or lifethreatening disease. It is recommended to administer
high-dose intravenous glucocorticoid (10–30 mg / kg / day
maximum 1 g) especially in patients who need high-dose
inotropes or multiple inotropes and / or vasopressors if
they do not respond to intravenous immunoglobulin and
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low-medium dose glucocorticoids. Low to medium dose
steroids (1–2m / kg / day) may be considered in patients
with milder forms of MIS-C with persistent fever and
symptoms despite a single IVIG dose. Once the patient has
recovered clinically, they can be switched to an equivalent
oral prednisolone or prednisone dose at discharge and
then reduced for three to four weeks. Anakinra (> 4 mg /
kg / day IV or subcutaneous) treatment may be considered
in patients who are unresponsive to MIS-C and MAS
who are unresponsive to intravenous immunoglobulin
and glucocorticoids and who are contraindicated to the
use of long-term glucocorticoids. Serial laboratory tests
and cardiac evaluation should guide immunomodulatory
treatment response and reduction of therapy. Patients may
need immunomodulatory medication for 2–3 weeks or
even longer.
In patients with MIS-C, low-dose aspirin (3–5 mg /
kg / day; maximum 81 mg / day) can be used until the
platelet count returns to normal, and normal coronary
arteries are confirmed 4 weeks after diagnosis. Aspirin
should be avoided in patients with active bleeding,
significant bleeding risk and / or platelet count ≤ 80,000 /
μL. However, patients with coronary artery aneurysm and
a maximum z-score of 2.5–10 are treated with low-dose
aspirin. In addition, patients with a Z-score of ≥ 10 should
be treated with low-dose aspirin as well as therapeutic
anticoagulation with enoxaparin (factor Xa level between
0.5–1) or warfarin. Longer use of enoxaparin dosage
indications includes Z-score> 10 (indefinite treatment),
with coronary artery aneurysm, documented thrombosis
(≥3 months of treatment awaiting thrombus resolution),
or moderate to severe ongoing left ventricular dysfunction.
Antiplatelet therapy or anticoagulant treatment can
be initiated in addition to IVIG in cases with incomplete
or complete KD feature. If there are findings of coronary
artery involvement, steroid therapy can be started. In
patients with documented thrombosis or ejection fraction
<35% should be given therapeutic anticoagulation with
enoxaparin for at least 2 weeks after discharge from
hospital.
Anakinra (recombinant human interleukin-1 receptor
antagonist), canakinumab (human anti-interleukin-1β
monoclonal antibody), and tocilizumab (anti-interleukin-6
receptor monoclonal antibody), in patients who are
unable to receive glucocorticoids and who are resistant
to glucocorticoids, are alternative options for treatment
before mechanical ventilation therapy and macrophage
activation syndrome. In the current case series, IL-1 and
IL-6 inhibitors have been used in approximately 10%–20%
of patients (19,34). Tocilizumab is not recommended in
most pediatric patients because of its long half-life and
lack of much benefit in studies in adults [40].

Children who develop shock are treated according
to shock protocols. Vasoconstrictor therapy such as
adrenaline and noradrenaline can be given to the patient
who is in the refractory shock clinic to fluid therapy.
Adrenaline may be preferred especially in patients with
left ventricular dysfunction. During periods, when the
disease is intense, patients should be closely monitored
for complications such as arrhythmia and embolism,
and, if necessary, they should be followed up by repeated
electrocardiogram, echocardiography, and cardiac enzyme
monitoring.
Patients with significant left ventricular dysfunction
are treated with intravenous diuretics and agents such
as milrinone, dopamine, and dobutamine. Mechanical
hemodynamic support in the form of extracorporeal
membrane oxygenation or a ventricular assist device may
be required in cases of fulminant disease [32].
Multiple systemic inflammatory syndrome may
present with signs and symptoms mimicking septic shock
and toxic shock syndrome (TSS). Therefore, patients
with severe multisystem involvement, especially those
with shock, should receive empirically broad-spectrum
antibiotic therapy, while the culture results are awaited.
An appropriate empirical regimen consists of ceftriaxone
and vancomycin. Clindamycin can be added if there are
toxin-mediated disease-like features. While SARS-CoV-2
antibody positivity is observed in most of the patients
with multiple systemic inflammatory syndrome, RT-PCR
positivity is seen in very few patients. Therefore, antiviral
therapy may reduce the severity of the disease in selected
RT-PCR positive cases.
9.Prognosis
Although multiple systemic inflammatory syndrome has
many similarities to KD and toxic shock syndrome, the
disease course in MIS-C can be more severe, and many
children may require intensive care intervention. Most
children survive, but there have been a few reported deaths
[40]. In a systematic review of 16 case series, including a
total of 655 MIS-C patients, 11 deaths (1.7%) occured [33].
Patients with a diagnosis of multiple systemic
inflammatory syndrome with abnormal BNP and / or
troponin T levels are recommended to be followed up until
these laboratory parameters reach normal values. Cardiac
electrical conduction abnormalities are increasingly being
reported in MIS-C. Therefore, in hospitalized MIS-C
patients, an ECG should be taken at least every 48 h
during the visit [39]. If there are conductive abnormalities
as a result of the electrocardiogram, patients should be
continuously monitored by cardiac monitoring, and
follow-up with Holter ECG should be considered. Z scores
indexed to body surface area should be measured using
echocardiograms, ventricular / valve functions, pericardial
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infusion, and coronary artery dimensions during diagnosis
and clinical follow-up. After discharge, children with
MIS-C will need a close clinical follow-up with cardiology.
Approximateliy 20% of patients with cardiac
involvement have continued mild suppression in cardiac
functions during discharge from the hospital [41]. Longterm complications of myocardial inflammation should

be carefully monitored for other forms of myocarditis.
In the acute phase of the disease, patients who present
with significant transient left ventricular dysfunction
(left ventricular injection fraction <50%) or persistent
left ventricular dysfunction are recommended to undergo
cardiac magnetic resonance imaging after 2–6 months in
order to show cardiac myocardial fibrosis and scar [32].

References
1. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz MK et
al. Coronavirus Disease 2019 Case Surveillance - United
States The Morbidity and Mortality Weekly Report. 2020;
69:759 doi: 10.15585/mmwr.mm6924e2
2.Dong Y, Mo X, Hu Y, Qi X, Jiang F et al. Epidemiology of COVID-19
Among Children in China. Pediatrics. 2020;145(6):e20200702.
doi: 10.1542/peds.2020-0702
3. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J
et al. Intensive care admissions of children with paediatric
inflammatory multisystem syndrome temporally associated
with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre
observational study. The Lancet Child and Adolescent Health.
2020 Sep;4(9):669-677. doi:10.1016/S2352-4642(20)30215-7
4. Center for Disease Control and Prevention, Center for Preparedness
and Response: Multisystem Inflammatory Syndrome in
Children (MIS-C) AssociatedwithCoronavirusDisease 2019
(COVID-19), ClinicianOutreachandCommunication (COCA)
Webinar. Website https://emergency.cdc.gov/coca/calls/2020/
callinfo_051920.asp?deliveryName=USCDC_105[accessed
May 2020].
5. Pediatric Intensive Care Society. PICS Statement: Increased
number of reported cases of novel presentation of multisystem inflammatory disease. Website :https://picsociety.
uk/wpcontent/uploads/2020/04/PICS-statement-re-novelKD-C19- presentation-v2-27042020.pdf. [accessed
April
2021].
6. Rae S.M. Yeung, Polly J. Ferguson.Is multisystem inflammatory
syndrome in children on the Kawasaki syndrome spectrum?
The Journal of Clinical Investigation 2020;130(11):56815684. https://doi.org/10.1172/JCI141718
7. National Center forImmunization and Respiratory Diseases
(NCIRD).Health Department-Reported Cases of Multisystem
Inflammatory Syndrome in Children (MIS-C) in the United
States. Website : https://stacks.cdc.gov/view/cdc/106439
[accessed August 2021].
8. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A
et al New York State and Centers for Disease Control and
Prevention Multisystem Inflammatory Syndrome in Children
Investigation Team. Multisystem Inflammatory Syndrome
in Children in New York State. The New England Journal of
Medicine. 2020;23: 347-358. doi: 10.1056/NEJMoa2021756

3282

9. Kim YJ, Park H, Choi YY, Kim YK, Yoon Y et al 2020. Defining
Association between COVID-19 and the
Multisystem
Inflammatory Syndrome in Children through the Pandemic
Journal of Korean Medicine. Sci. 35:e204. doi:10.3346/
jkms.2020.35.e204
10. Li Y,Zheng Q, Zou L, Wu J, Guo L et al. Kawasaki disease shock
syndrome: clinical characteristics and possibleuse of IL-6, IL10 and IFN-γ as biomarkers for early recognition. Pediatric
Rheumatology. 2019;17:1-9. doi:10.1186/s12969-018-0303-4
11. Brodin P. Why is COVID-19 somild in children? Acta Paediatrica.
2020;109(6):1082-1083. doi: 10.1111/apa.15271
12. Ludvigsson JF. Systematic review of COVID-19 in children
shows milder cases and a better prognosis than adults. Acta
Paediatrica. 2020;109(6):1088-1095. doi: 10.1111/apa.15270
13. Weisberg SP, Connors T, Zhu Y, Baldwin M, Lin W-H et al.
Antibody responses to SARS-CoV2 are distinct in children
with MIS-C compared to adults with COVID-19. medRxiv.
2020; Jul 14;07.12.20151068. doi: 10.1101/2020.07.12.20151068
14. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S
et al. Virological assessment of hospitalized patients with
COVID-2019. Nature. 2020;581(7809):465-9.doi: 10.1038/
s41586-020-2196-x
15. Duarte-Neto AN, Caldini EG, Gomes-Gouvêa MS, Kanamura
CT, de AlmeidaMonteiro et al.
An autopsystudy of
thespectrum of severe COVID-19 in children: From
SARS todifferentphenotypes of MIS-C. E Clinical
Medicine.2021;35:100850. doi: 10.1016/j.eclinm.2021.100850
16. Schwartz M. MIS-C: post-infectious syndrome or persistent
infection? The Lancet Infectious Diseases. 2021;21(5):e116.
doi: 10.1016/S1473-3099(20)30786-6
17. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D et al.
The immunology of multisystem inflammatory syndrome in
children with COVID-19. Cell. 2020;183(4):968-81. e7.doi:
10.1016/j.cell.2020.09.016
18. Noval Rivas M, Porritt RA, Cheng MH, Bahar I, Arditi M.
COVID-19-associated multisystem inflammatory syndrome
in children (MIS-C): A novel disease that mimics toxic
shock syndrome-the superantigen hypothesis. The Journal
of Allergy and Clinical Immunology . 2021;147(1):57-59.
doi:10.1016/j.jaci.2020.10.008

HANÇERLİ TÖRÜN et al. / Turk J Med Sci
19. Hamming I, Timens W, Bulthuis M, Lely A, Navis G et al. Tissue
distribution of ACE2 protein, the functional receptor for SARS
coronavirus. A first step in understanding SARS pathogenesis.
The Journal of Pathology: Reviews in Medical Microbiology
2004;203(2):631-7.doi: 10.1002/path.1570
20. Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from
SARS: control of acute lung failure by the SARS receptor ACE2
The Journal of Molecular Medicine. 2006;84(10):814-20.doi:
10.1007/s00109-006-0094-9
21. Chang LY, Lu CY, Shao PL, Lee PI, Lin MT et al. Viral infections
associated with Kawasaki disease. J Formos Med Assoc.
2014;113(3):148-54.doi: 10.1016/j.jfma.2013.12.008
22. Xu Z, Shi L, Wang Y, Zhang J, Huang L,et al. Pathological findings
of COVID-19 associated with acute respiratory distress
syndrome. The Lancet Respiratory Medicine2020;8(4):420-2.
doi: 10.1016/S2213-2600(20)30076-X
23. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A et al.
Acute heart failure in multisystem inflammatory syndrome
in children (MIS-C) in the context of global SARS-CoV-2
pandemic. Circulation. 2020; Aug 4;142(5):429-436. doi:
10.1161/cırculatıonaha.120.048360
24. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM
et al. Multisystem inflammatory syndrome in US children
and adolescents. The New England Journal of Medicine.
2020;383(4):334-46.doi: 10.1056/NEJMoa2021680
25. Carlin RF, Fischer AM, Pitkowsky Z, Abel D, Sewell TB et al.
Discriminating MIS-C Requiring Treatment from Common
Febrile Conditions in Outpatient Settings. The Journal of
Pediatrics2020;229:26-32. doi: 10.1016/j.jpeds.2020.10.013
26. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK
et al. American College of Rheumatology Clinical Guidance
for Pediatric Patients with Multisystem Inflammatory
Syndrome in Children (MIS-C) Associated with SARSCoV-2 and Hyperinflammation in COVID-19. Version 2.
Arthritis & Rheumatology. 2020;73(4):13-29.doi: 10.1002/
art.41616
27. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE et al.
Clinical Characteristics of 58 Children With a Pediatric
Inflammatory Multisystem Syndrome Temporally Associated
With SARS-CoV-2. Jama. 2020;324(3):259-269. doi: 10.1001/
jama.2020.10369
28. Blumfield E, Levin TL, Kurian J, Lee EY, Liszewski MC.
ImagingFindings in MultisystemInflammatorySyndrome
in Children (MIS-C) AssociatedWithCoronavirusDisease
(COVID-19). American journal of roentgenology.
2021;216(2):507-517. doi: 10.2214/AJR.20.24032
29. Alsaied T, Tremoulet AH, Burns JC, Saidi A, Dionne A et
al.Review of Cardiac Involvement in Multisystem Inflammatory
Syndrome in Children. Circulation. 2021; 5;143(1):78-88. doi:
10.1161/CIRCULATIONAHA.120.049836
30. Lin KH, Chang SS, Yu CW, Lin SC, Liu SC et al. Usefulness
of natriuretic peptide for the diagnosis of Kawasaki
disease: a systematic review and meta-analysis. BMJ open.
2015;5(4):e006703. doi: 10.1136/bmjopen-2014-006703

31. Grom AA, Horne A, De Benedetti F. Macrophage
activation syndrome in the era of biologic therapy.
Nature Reviews Rheumatology. 2016; 12(5):259-68.doi:
10.1038/nrrheum.2015.179
32. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK
et al. American College of Rheumatology Clinical Guidance for
Multisystem Inflammatory Syndrome in Children Associated
With SARS-CoV-2 and Hyperinflammation in Pediatric
COVID-19: Version 2. Arthritis & rheumatology (Hoboken,
NJ). 2021;73(4):e13-e29. doi: 10.1002/art.41454
33. Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A systematic
review of multisystem inflammatory syndrome in children
associated with SARS-CoV-2 infection. The Pediatric
infectious disease journal. 2020;39(11):e340-e6. doi: 10.1097/
INF.0000000000002888
34. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose
EB et al. Characteristics and Outcomes of US Children and
Adolescents With Multisystem Inflammatory Syndrome in
Children (MIS-C) Compared With Severe Acute COVID-19.
JAMA.2021;325(11):1074. doi:10.1001/jama.2021.2091
35. Irfan O, Muttalib F, Tang K, Jiang L, Lassi ZS et al.Clinical
characteristics, treatment and outcomes of paediatric
COVID-19: a systematic review and meta-analysis. Archives
of Disease in Childhood 2021;16;106(5):440–8. doi: 10.1136/
archdischild-2020-321385
36 World Health Organization. Multisystem inflammatory syndrome
in children and adolescents with COVID-19: Scientific Brief.
2020.
website:
https://www.who.int/publications-detail/
multisystem-inflammatory-syndrome-in-children-andadolescents-with-covid-19 [accessed May 2021].
37. Cirks BT, Rowe SJ, Jiang SY, Brooks RM, Mulreany MP et al.
16 Weeks Later: Expanding the Risk Period for MIS-C. The
official journal of the Pediatric Infectious Diseases Society.
2021; May 28;10(5):686-690. doi: 10.1093/jpids/piab007
38. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L et al.
COVID-19-Associated Multisystem Inflammatory Syndrome
in Children - United States, March-July 2020. The Morbidity
and Mortality Weekly Report. 2020;69(32):1074 doi: 10.15585/
mmwr.mm6932e2
39. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG et
al. Multisystem inflammatory syndrome related to COVID-19
in previously healthy children and adolescents in New York
City. Jama. 2020;21;324(3):294-6 doi: 10.1001/jama.2020.10374
40. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C
et al. Impact of low dose tocilizumab on mortality rate in
patients with COVID-19 related pneumonia. European
journal of internal medicine. 2020 June;76:31-5 doi: 10.1016/j.
ejim.2020.05.009
41. Capone CA, Subramony A, Sweberg T, Schneider J, Shah S et
al. Characteristics, cardiac involvement, and outcomes of
multisystem inflammatory syndrome of childhood associated
with severe acute respiratory syndrome coronavirus 2 infection.
The Journal of Pediatrics. 2020 Sep;224:141-5 doi: 10.1016/j.
jpeds.2020.06.044

3283

